Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN).
K. B. Blagoev
No relevant relationships to disclose
J. Wilkerson
No relevant relationships to disclose
W. D. Stein
No relevant relationships to disclose
R. J. Motzer
Research Funding - Pfizer
S. E. Bates
No relevant relationships to disclose
A. T. Fojo
No relevant relationships to disclose